Dergiler / Turkish Journal of Medical Sciences / 2019 / Cilt: 49 - Sayı: 4

Prognostic importance of PTEN, EGFR, HER-2, and IGF-1R in gastric cancer patients treated with postoperative chemoradiation

Sayfa
1025–1032
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The median DFS was 29.2 months for IGF-1R (+) patients, 37.9 months for those with IGF-1R (-), and 26.3 and 40.59months for smokers and nonsmokers, respectively.Conclusion: IGF-1R and EGFR may be used for patient selection in future prospective studies that evaluate the prognostic importanceof these receptors.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: This study aimed to describe the prognostic importance of epidermal growth factor (EGFR), phosphatase and tensinhomolog (PTEN), human EGF receptor-2 (HER-2), and insulin-like growth factor 1 receptor (IGF-1R) in gastric cancer patients treatedwith postoperative chemoradiation therapy.Materials and methods: Sixty-nine patients treated with adjuvant chemoradiation therapy were retrospectively evaluated.
📊
Temel Bulgular & Veri:Tumorsamples were stained immunohistochemically.Results: All patients were treated with 3D conformal radiation therapy with concomitant and adjuvant chemotherapy.
💡
Sonuç & Katkı:The median DFS was 29.2 months for IGF-1R (+) patients, 37.9 months for those with IGF-1R (-), and 26.3 and 40.59months for smokers and nonsmokers, respectively.Conclusion: IGF-1R and EGFR may be used for patient selection in future prospective studies that evaluate the prognostic importanceof these receptors.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: This study aimed to describe the prognostic importance of epidermal growth factor (EGFR), phosphatase and tensinhomolog (PTEN), human EGF receptor-2 (HER-2), and insulin-like growth factor 1 receptor (IGF-1R) in gastric cancer patients treatedwith postoperative chemoradiation therapy.Materials and methods: Sixty-nine patients treated with adjuvant chemoradiation therapy were retrospectively evaluated. Tumorsamples were stained immunohistochemically.Results: All patients were treated with 3D conformal radiation therapy with concomitant and adjuvant chemotherapy. Perineuralinvasion (PNI) (P = 0.042), prechemoradiation therapy albumin levels below 3.5 mg/dL (P = 0.011), and EGFR positivity (P = 0.008) hadnegative effects on overall survival (OS). The median OS was 26 months for patients with PNI (+), 34.9 months for those with PNI (–),19.5 months for those with albumin levels below 3.5 mg/dL, and 33.2 months for those with albumin levels above 3.5 mg/dL. IGF-1R (+)(P = 0.035) and history of cigarette smoking (P = 0.033) were observed to have a statistically significantly negative effect on disease-freesurvival (DFS). The median DFS was 29.2 months for IGF-1R (+) patients, 37.9 months for those with IGF-1R (-), and 26.3 and 40.59months for smokers and nonsmokers, respectively.Conclusion: IGF-1R and EGFR may be used for patient selection in future prospective studies that evaluate the prognostic importanceof these receptors.

🔖

Bu Makaleye Atıf Yap

KANYILMAZ, G., AKTAN, M., KOÇ, M., KOZACIOĞLU, S., YAVUZ, B. B. (2022). Prognostic importance of PTEN, EGFR, HER-2, and IGF-1R in gastric cancer patients treated with postoperative chemoradiation. Turkish Journal of Medical Sciences, Cilt: 49 - Sayı: 4, 1025–1032. https://ajindex.com/articles/610919

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clinical Cancer Research 2012
  2. 18 (21): 5992-6000. doi: 10.1158/1078-0432.CCR-12-1318 2. Gunderson L, Tepper J. Clinical Radiation Oncology. 4th ed. Philadelphia, PA, USA: Elsevier
  3. Kim TH, Park SR, Ryu KW, Kim YW, Bae JM et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. International Journal of Radiation Oncology Biology Physics 2012
  4. 84 (5): 585-592. doi: 10.1016/j.ijrobp.2012.07.2378 4. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC et al. Chemotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine 2001
  5. 345 (10): 725-730. doi:10.1056/NEJMoa010187 5. Brady LW, Heilmann HP, Molls M, Nieder C. Radiation Oncology: An Evidence-Based Approach. Berlin, Germany: Springer
  6. Atmaca A, Werner D, Pauliqk C, Steinmetz K, Wirtz R et al. The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer 2012
  7. doi: 10.1186/1471-2407-12-524 7. Oh HS, Eom DW, Kang GH, Ahn YC, Lee SJ et al. Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection. Gastric Cancer 2014
  8. 17 (3): 402-411. doi: 10.1007/s10120-013-0288-0 8. Pathmanathan N, Geng JS, Li W, Nie X, Veleso J et al. Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study. AsiaPacific Journal of Clinical Oncology 2017
  9. 13 (3): 249-260. doi: 10.1111/ajco.12653 9. Boku N. HER2–positive gastric cancer. Gastric Cancer 2014
  10. 17 (1): 1-12. doi: 10.1007/s10120-013-0252-z 10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER-2 positive advanced gastric or gastrooesophageal junction cancer (TOGA): a phase 3, open-label, randomized controlled trial. Lancet 2010
  11. 376 (9742): 687-697. doi: 10.1016/S0140-6736(10)61121-X 11. Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT et al. Impact of insulin-like growth factor type 1-receptor, epidermal growth fact